Hemab Raises $135m To Advance Clinical Strategy In Bleeding And Thrombotic Disorders
Fresh Capital Funds Operations Through 2025
Executive Summary
Hemab’s series B financing will fund its lead program, currently in Phase I/II for Glanzmann thrombasthenia, as it moves into pivotal testing plus at least one other asset heading into the clinic.